pbs_code
stringlengths 5
6
| drug
stringclasses 15
values | brand
stringclasses 29
values | formulation
stringclasses 35
values | indication
stringclasses 7
values | treatment_phase
stringclasses 53
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.03k
4.03k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
12796L | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13295R | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | juvenile idiopathic arthritis | Continuing treatment | 14155 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
11489Q | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11489Q | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11489Q | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
13339C | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | 14164 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
13699B | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14604 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13722F | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10897M | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13214L | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13214L | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12444Y | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12425Y | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12425Y | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12425Y | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12425Y | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12425Y | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12425Y | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12425Y | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12425Y | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12425Y | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13725J | abatacept | Orencia | Powder for I.V. infusion 250 mg | rheumatoid arthritis | Subsequent continuing treatment | 14604 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
12417M | adalimumab | Amgevita | Injection 20 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
10890E | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10890E | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10890E | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10892G | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12328W | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12415K | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12415K | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12415K | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12415K | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12415K | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12576X | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled syringe | rheumatoid arthritis | Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13216N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13216N | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11748H | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12102Y | tocilizumab | Actemra Subcutaneous Injection | Injection 162 mg in 0.9 mL single use pre-filled syringe | juvenile idiopathic arthritis | Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13209F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13209F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13770R | tofacitinib | Xeljanz | Oral solution 1 mg per mL, 240 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13770R | tofacitinib | Xeljanz | Oral solution 1 mg per mL, 240 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13770R | tofacitinib | Xeljanz | Oral solution 1 mg per mL, 240 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13770R | tofacitinib | Xeljanz | Oral solution 1 mg per mL, 240 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11324B | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11324B | certolizumab pegol | Cimzia | Solution for injection 200 mg in 1 mL pre-filled pen | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13696W | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Subsequent continuing treatment | 14485 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
10909E | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | psoriatic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10909E | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | psoriatic arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10909E | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | psoriatic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13077G | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12390D | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12390D | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12390D | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12390D | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12390D | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12390D | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9458T | etanercept | Brenzys | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9458T | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |